Cynthia M. Butitta - Aug 26, 2025 Form 4 Insider Report for UroGen Pharma Ltd. (URGN)

Role
Director
Signature
/s/ Jason D. Smith, Attorney-in-Fact
Stock symbol
URGN
Transactions as of
Aug 26, 2025
Transactions value $
$0
Form type
4
Date filed
8/27/2025, 04:37 PM
Previous filing
Jun 16, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
BUTITTA CYNTHIA M Director 400 ALEXANDER PARK DRIVE, PRINCETON /s/ Jason D. Smith, Attorney-in-Fact 2025-08-27 0001222082

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction URGN Stock Option (right ot buy) Award $0 +10K $0.00 10K Aug 26, 2025 Ordinary Shares 10K $19.50 Direct F1
transaction URGN Restricted Stock Unit Award $0 +8K $0.00 8K Aug 26, 2025 Ordinary Shares 8K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying the stock option will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates.
F2 Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer
F3 The shares underlying the RSUs will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates.